昱展新药(6785)行研发的Ketamine(氯胺酮)缓释注射剂ALA-3000通过美国食品药物管理署(FDA)新药临床试验(IND)申请审查，核准执行于难治型忧郁症(Treatment-resistant depression, TRD)的临床I/IIa期试验。昱展新药开发 ...

A rare autoimmune disorder was behind Mr Hazwady Nazran's paranoid delusions, memory loss and seizures. Read more at ...

Researchers have developed a cellular fractionation protocol. This method allows for precise analysis of the proteins located ...

In this study, recently published in Alzheimer's & Dementia, the authors investigated NMDA (N-methyl-D-aspartate receptors) receptors due to their importance in synaptic transmission and their ...

Researchers from the Institute for Neurosciences (IN), a joint center of the Miguel Hernández University of Elche (UMH) and ...

Apimostinel has a similar mode of action to ketamine and derivatives like Johnson & Johnson's Spravato (esketamine) – ...

Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and ...

Relmada halted Phase 3 trials of NMDA receptor blocker for depression but will continue its early psilocybin program while ...

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS) and metabolic disorders. Relmada’s experienced and dedicated team is committed to ...

Shares of Relmada Therapeutics Inc. (NASDAQ:RLMD) plummeted 77% to close at 63 cents Dec. 4 after a pre-planned interim analysis prompted the independent data monitoring committee to conclude the ...

If you're struggling to sleep, you've probably tried a number of methods to help you drift off - but one doctor shared a ...